ICICI Direct has come out with its second quarter (July-September’ 21) earnings estimates for the Healthcare sector. The brokerage house expects Alembic Pharma to report net profit at Rs 169.4 crore down 49.2% year-on-year (up 2.9% quarter-on-quarter).
Net Sales are expected to decrease by 6.5 percent Y-o-Y (up 2.8 percent Q-o-Q) to Rs 1,363 crore, according to ICICI Direct.
Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to fall by 45 percent Y-o-Y (up 3.4 percent Q-o-Q) to Rs 244 crore.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
Read More
